TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16924528

Group type: EXPERIMENTAL
Intervention: Bedrest for 14 days
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Bedrest for 42 days
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Bedrest for 90 days
Number of subjects: 26

Group type: COMPARATOR
Intervention: Bedrest for 14 days and 42 days
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Longer bedrest durations
Number of subjects: 26
Study: 14729722

Group type: EXPERIMENTAL
Intervention: Opioid-receptor antagonist (16 mg naloxone)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Opioid-receptor agonist (60 mg codeine)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 34
Study: 11401635

Group type: EXPERIMENTAL
Intervention: Pinguecula patients
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57
Study: 9107219

Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenge (DBPCFC)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Skin-prick tests
Number of subjects: 105

Group type: COMPARATOR
Intervention: Western blot tests
Number of subjects: 105

Group type: COMPARATOR
Intervention: RAST
Number of subjects: 105
Study: 7686065

Group type: EXPERIMENTAL
Intervention: Transurethral microwave treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 40
Study: 2826749

Group type: EXPERIMENTAL
Intervention: Dentifrice consisting of sodium bicarbonate and 3% hydrogen peroxide or 3% hydrogen peroxide alone with 5 M NaCl irrigating solution
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dentifrice consisting of sodium bicarbonate and 3% hydrogen peroxide or 3% hydrogen peroxide alone with distilled water as irrigant
Number of subjects: 10
Study: 29313172

Group type: EXPERIMENTAL
Intervention: Increased knowledge of recovery
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Self-reported PCCP behaviors
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Objective fidelity measures
Number of subjects: 224
Study: 26906278

Group type: EXPERIMENTAL
Intervention: Neurofeedback training (NFT) with a motor imagery-based BCI (MI-BCI)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no NFT)
Number of subjects: 63
Study: 25032220

Group type: EXPERIMENTAL
Intervention: Posterior foot placement
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hands on thigh position
Number of subjects: 45
Study: 24171260

Group type: EXPERIMENTAL
Intervention: 3 g P. tuberosa in two divided doses
Number of subjects: 15

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 15
Study: 20826076

Group type: EXPERIMENTAL
Intervention: Juvenile drug court (JDC) intervention
Number of subjects: 118
Study: 18096841

Group type: EXPERIMENTAL
Intervention: Small vessel VaD
Number of subjects: 706

Group type: EXPERIMENTAL
Intervention: Large vessel VaD
Number of subjects: 706

Group type: EXPERIMENTAL
Intervention: Overall neurological signs
Number of subjects: 706
Study: 19369186

Group type: EXPERIMENTAL
Intervention: Six acupuncture points (ST35, EX‐LE4, ST36, SP9, SP10, ST34)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Two acupuncture points (ST35, EX‐LE4)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Both groups allowed to take 200 mg celecoxib per day
Number of subjects: 70

Group type: COMPARATOR
Intervention: Global assessment of change after 10 treatments
Number of subjects: 70

Group type: COMPARATOR
Intervention: Body weight change
Number of subjects: 70
Study: 15889022

Group type: EXPERIMENTAL
Intervention: Pegged components
Number of subjects: 43

Group type: COMPARATOR
Intervention: Keeled components
Number of subjects: 43
Study: 12468605

Group type: EXPERIMENTAL
Intervention: Lutein diester formulation (0.67 micro mol lutein/kg body)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Unesterified lutein formulation (0.5 micro mol lutein/kg body)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oil-solubilized unesterified lutein preparation (0.5 micro mol/kg body)
Number of subjects: 18
Study: 9469323

Group type: EXPERIMENTAL
Intervention: Pure antiandrogen plus placebo (A+P group)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Luteinizing hormone-releasing hormone (LHRH) agonist plus placebo (LHRH+P group)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Pure antiandrogen plus LHRH agonist (A+LHRH group)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo plus placebo (P+P group)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Overall survival comparison among the four arms
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Anandron-containing regimens
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: LHRH-containing regimens
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 244
Study: 7848897

Group type: EXPERIMENTAL
Intervention: NTG patches delivering low (15-30 mg/24 hr)
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: NTG patches delivering moderate (45-60 mg/24 hr)
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: NTG patches delivering large (75 and 105 mg/24 hr)
Number of subjects: 562

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 562
Study: 2970362

Group type: EXPERIMENTAL
Intervention: Water restriction (1.0 litre total water intake/24 h)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Water loading (6.8 litres total water intake/24 h)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (2.7 litres water/24 h)
Number of subjects: 9
Study: 11799261

Group type: EXPERIMENTAL
Intervention: cerivastatin (0.15 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 31727881

Group type: EXPERIMENTAL
Intervention: Genetic variance influencing cortical thickness in the right dorsal lateral prefrontal cortex (DLFPC) sulci and gyri, ventral posterior cingulate cortex (PCC), pre-somatic motor cortex (PreSMA), medial precuneus, left occipital-temporal junction (OTJ), parietal-temporal junction (PTJ), ventral somatosensory cortex (vSMA), and medial and lateral precuneus.
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Split-half replication of DLPFC clusters.
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Meta-analytic term search.
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Gene and transcript mapping/enrichment analyses.
Number of subjects: 258
Study: 29929783

Group type: EXPERIMENTAL
Intervention: REGN3470-3471-3479
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 26994756

Group type: EXPERIMENTAL
Intervention: PAV+ (Patient-Activated Ventilation Plus)
Number of subjects: 108

Group type: COMPARATOR
Intervention: CMV (Controlled Mechanical Ventilation)
Number of subjects: 108
Study: 25268370

Group type: EXPERIMENTAL
Intervention: BEV-PAC (bevacizumab 10 mg kg(‐1) days 1 and 15 plus paclitaxel 90 mg m(‐2) days 1, 8 and 15 q4w)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BEV-CAP (bevacizumab 15 mg kg(‐1) day 1 plus capecitabine 1000 mg m(‐2) bid days 1‐14 q3w)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BEV-PAC
Number of subjects: 0

Group type: COMPARATOR
Intervention: BEV-CAP
Number of subjects: 0
Study: 22518377

Group type: EXPERIMENTAL
Intervention: 6 mm-long, 4 mm-wide implants
Number of subjects: 40

Group type: COMPARATOR
Intervention: at least 10 mm-long implants in augmented bone
Number of subjects: 40
Study: 20400406

Group type: EXPERIMENTAL
Intervention: Peg-IFN alfa-2a / ribavirin
Number of subjects: 289
Study: 17509302

Group type: EXPERIMENTAL
Intervention: 25 mg/m2 docetaxel (arm A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 25 mg/m2 vinorelbine (arm B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Second line vinorelbine after progression to docetaxel
Number of subjects: 40

Group type: COMPARATOR
Intervention: Second line docetaxel after progression to vinorelbine
Number of subjects: 40
Study: 15949359

Group type: COMPARATOR
Intervention: Routine hyperoxic CPB (FiO2 of 1.0)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Modified CPB with graded reoxygenation (FiO2 of 0.21 increased to 30%-60% over 5-10 minutes)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 12375715

Group type: EXPERIMENTAL
Intervention: Suplatast tosilate (100 mg t.i.d. for 28 days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 28
Study: 10980831

Group type: EXPERIMENTAL
Intervention: Intervention with agents that lower triglycerides and raise HDL
Number of subjects: 0

Group type: COMPARATOR
Intervention: High triglyceride levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fasting triglyceride levels
Number of subjects: 0
Study: 8850385

Group type: EXPERIMENTAL
Intervention: Once-daily diltiazem CD
Number of subjects: 95

Group type: COMPARATOR
Intervention: Twice-daily diltiazem SR
Number of subjects: 95
Study: 2185042

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) with clomiphene citrate (CC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) with spontaneous cycles
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Timed intercourse with clomiphene citrate (CC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Timed intercourse with spontaneous cycles
Number of subjects: 40
Study: 74317

Group type: EXPERIMENTAL
Intervention: Alcohol intoxication (1 g/kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Alcohol plus pyrithioxine (7 mg/kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Pyrithioxine (7 mg/kg) plus alcohol
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31430183

Group type: EXPERIMENTAL
Intervention: 290-NBI
Number of subjects: 117

Group type: COMPARATOR
Intervention: HDWL
Number of subjects: 117
Study: 30234616

Group type: EXPERIMENTAL
Intervention: Clostridium butyricum MIYAIRI 588 (CBM588) 60 mg/d in combination with antidepressants
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 40
Study: 26723854

Group type: EXPERIMENTAL
Intervention: Mirror therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional stroke rehabilitation program
Number of subjects: 30
Study: 24156501

Group type: EXPERIMENTAL
Intervention: Scripts depicting efforts by a middle-aged daughter to raise the topic of future care needs with her mother by implementing a variety of facework behaviors
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Scripts with varying degrees of respect for mother's autonomy and connection
Number of subjects: 130
Study: 22376375

Group type: EXPERIMENTAL
Intervention: CONNECT + FALLS
Number of subjects: 16

Group type: COMPARATOR
Intervention: FALLS
Number of subjects: 16
Study: 20621945

Group type: EXPERIMENTAL
Intervention: Cognitive Intervention Group (CIG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo Group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Untreated Group
Number of subjects: 40
Study: 18158814

Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 40 mcg/kg granisetron
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 15 mcg/kg ondansetron
Number of subjects: 75
Study: 16338566

Group type: EXPERIMENTAL
Intervention: Bilateral blue light-filtering intraocular lens (IOL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Similar IOL that does not filter blue light
Number of subjects: 0
Study: 16325621

Group type: EXPERIMENTAL
Intervention: Surgical intervention for stress incontinence
Number of subjects: 650
Study: 11491155

Group type: EXPERIMENTAL
Intervention: Salmeterol (42 microg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ipratropium (36 microg)
Number of subjects: 16
Study: 9565268

Group type: EXPERIMENTAL
Intervention: Guided Bone Regeneration with resorbable membrane (n=10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Guided Bone Regeneration with nonresorbable membrane (n=10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group treated by enucleation and primary closure (n=10)
Number of subjects: 30
Study: 7840721

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 3048216

Group type: EXPERIMENTAL
Intervention: Artificial dermis
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control (investigator's usual skin grafting material)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control
Number of subjects: 106
Study: 29882073

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 3-monthly (PP3M)
Number of subjects: 1161

Group type: COMPARATOR
Intervention: Paliperidone palmitate 1-monthly (PP1M)
Number of subjects: 1161
Study: 28470156

Group type: EXPERIMENTAL
Intervention: Relapse Prevention Program (RPP), 3 one-hour sessions over 10 days prior to discharge
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no RPP)
Number of subjects: 54
Study: 25040766

Group type: EXPERIMENTAL
Intervention: 0.25% sodium hypochlorite oral rinse (15 mL, twice a week for 3 months)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water rinse (control group)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.25% sodium hypochlorite oral rinse
Number of subjects: 12
Study: 23276660

Group type: EXPERIMENTAL
Intervention: Umeclidinium 250μg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Umeclidinium 500μg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Umeclidinium 1000μg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Tiotropium bromide 18μg
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Umeclidinium 250μg (repeat dose)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Umeclidinium 1000μg (repeat dose)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (repeat dose)
Number of subjects: 62
Study: 20738470

Group type: EXPERIMENTAL
Intervention: Group A (feedback + health letter)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Group B (health letter only)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Group C (control group)
Number of subjects: 105
Study: 17964576

Group type: EXPERIMENTAL
Intervention: 1 mg of 17-beta estradiol orally for 1 month then 2 mg for 2 months
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Estradiol treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo pills
Number of subjects: 22

Group type: COMPARATOR
Intervention: Antimuscarinic drug scopolamine (SCOP)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Antinicotinic drug mecamylamine (MECA)
Number of subjects: 22
Study: 16569537

Group type: EXPERIMENTAL
Intervention: Temocapril (2 mg/d)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Candesartan (8 mg/d)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24
Study: 12749831

Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 11135211

Group type: EXPERIMENTAL
Intervention: Doxorubicin 40 mg/m(2) and cyclophosphamide 600 mg/m(2) intravenously every 3 weeks (AC)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Cyclophosphamide 100 mg/m(2) orally on Days 1-14, methotrexate 40 mg/m(2) and 5-fluorouracil 500 mg/m(2) intravenously on Days 1 and 8 every 4 weeks (CMF)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Doxorubicin and cyclophosphamide (AC)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)
Number of subjects: 124

Group type: COMPARATOR
Intervention: CMF
Number of subjects: 124
Study: 9370408

Group type: EXPERIMENTAL
Intervention: Retrograde cold blood cardioplegia (RCBC)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Antegrade cold blood cardioplegia (ACBC)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 158
Study: 1437685

Group type: EXPERIMENTAL
Intervention: Microfilled composite resin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Light-cured glass-ionomer liner and microfilled resin (sandwich technique)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Light-cured glass-ionomer liner only
Number of subjects: 0
Study: 3932509

Group type: EXPERIMENTAL
Intervention: Controlled diet supplemented with 2000 kCal and 10 g nitrogen daily (branched chain amino acid enriched formulation)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Controlled diet alone (Control)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Supplemented groups (branched chain amino acids)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Enteral or parenteral branched chain amino acids
Number of subjects: 64
Study: 31229634

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24IU)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 71
Study: 28372849

Group type: EXPERIMENTAL
Intervention: Protein hydrolysate drink (8.5 g before breakfast and 8.5 g before dinner)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo drink (identical in appearance and taste, lacking carbohydrate, fat or protein)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Protein hydrolysate drink
Number of subjects: 26
Study: 26872077

Group type: EXPERIMENTAL
Intervention: Eszopiclone 3 mg
Number of subjects: 199

Group type: COMPARATOR
Intervention: Zopiclone 7.5 mg
Number of subjects: 199
Study: 24215127

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of ranibizumab (0.5 mg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control subjects (healthy subjects)
Number of subjects: 39
Study: 22409311

Group type: EXPERIMENTAL
Intervention: Mnemonic strategy training
Number of subjects: 49

Group type: COMPARATOR
Intervention: Matched exposure control
Number of subjects: 49
Study: 19756418

Group type: EXPERIMENTAL
Intervention: Tobramycin once daily (treatment B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tobramycin thrice daily (treatment A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 30
Study: 17605571

Group type: EXPERIMENTAL
Intervention: Implementation intention prompt
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 55
Study: 15837983

Group type: COMPARATOR
Intervention: FEC 50 (fluorouracil 500 mg/m2, cyclophosphamide 500 mg/m2, epirubicin 50 mg/m2)
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: FEC 100 (fluorouracil 500 mg/m2, cyclophosphamide 500 mg/m2, epirubicin 100 mg/m2)
Number of subjects: 565
Study: 12901530

Group type: EXPERIMENTAL
Intervention: 0.15% tetracaine
Number of subjects: 43

Group type: COMPARATOR
Intervention: 0.3% ropivacaine
Number of subjects: 43
Study: 9878641

Group type: EXPERIMENTAL
Intervention: Inhaled tobramycin (300 mg, twice daily for four weeks)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study: 8924741

Group type: EXPERIMENTAL
Intervention: Enriched enteral diet (n=26)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standard enteral formula (n=24)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Total parenteral nutrition (n=27)
Number of subjects: 77
Study: 1851577

Group type: COMPARATOR
Intervention: lonidamine (A)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: mitomycin‐C/vindesine (B)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: mitomycin‐C/vindesine plus lonidamine (C)
Number of subjects: 184
Study: 7152080

Group type: EXPERIMENTAL
Intervention: Diprosalic lotion (betamethasone dipropionate and salicylic acid)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Dermovate lotion (clobetasol propionate)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 51
Study: 6317816

Group type: EXPERIMENTAL
Intervention: Multimodal lecture (auditory, visual, and tactile senses)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Formal lecture (auditory sense only)
Number of subjects: 43
Study: 31293199

Group type: EXPERIMENTAL
Intervention: W-GEE (weighted generalized estimating equation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MMI-GEE (multilevel multiple imputation for GEE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CW-GEE (clustering weighted generalized estimating equation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: W-GEE
Number of subjects: 0
Study: 28817231

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg and 0.75 mg
Number of subjects: 0
Study: 27981279

Group type: EXPERIMENTAL
Intervention: Intra-articular platelet-rich plasma (PRP) (3 ml)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Intra-articular hyaluronic acid (HA) (30 mg/2 ml; 1,000-2,900 kDa)
Number of subjects: 43
Study: 25549681

Group type: EXPERIMENTAL
Intervention: Dioscorea modified pill
Number of subjects: 100

Group type: COMPARATOR
Intervention: Aricept
Number of subjects: 100
Study: 22734375

Group type: EXPERIMENTAL
Intervention: Modified nursing group (n=248)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Conventional nursing group (n=124)
Number of subjects: 372
Study: 19620184

Group type: EXPERIMENTAL
Intervention: K-wire group (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cast group (n = 30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 60
Study: 18242485

Group type: EXPERIMENTAL
Intervention: Adenosine infusion (140 microg/kg/min)
Number of subjects: 54
Study: 15606446

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents
Number of subjects: 13

Group type: COMPARATOR
Intervention: Bare metal stents
Number of subjects: 13
Study: 11496732

Group type: EXPERIMENTAL
Intervention: Tiklid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: ADP, PHA-P, WGA, Con A
Number of subjects: 0
Study: 9781802

Group type: EXPERIMENTAL
Intervention: Oral IFN-alpha (200 IU daily sublingual dose)
Number of subjects: 30
Study: 7828634

Group type: EXPERIMENTAL
Intervention: Intravenously injected hyaluronan (HA)
Number of subjects: 12
Study: 3418660

Group type: EXPERIMENTAL
Intervention: Pressure at P6 (Neiguan) acupuncture point
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Pressure at a point near the right elbow (dummy pressure)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 350